timothy sykes logo

Stock News

Aquestive Therapeutics Stock Soars on FDA Approval News

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 9/21/2025, 12:18 pm ET 9/21/2025, 12:18 pm ET | 5 min 5 min read
Aquestive Therapeutics Stock Soars on FDA Approval News Thumbnail

Aquestive Therapeutics Inc.’s stocks have been trading up by 15.34 percent, fueled by positive news and investor optimism.

Healthcare industry expert:

Analyst sentiment – positive

Aquestive Therapeutics (AQST) is currently in a precarious market position marked by significant challenges in profitability and a weak financial structure. Key profitability ratios present a concerning picture, with negative EBIT margin (-130.8), EBITDA margin (-111.1), and profit margins, underscoring substantial operational inefficiencies. Despite a gross margin of 61.1%, the negative net income reflects underlying operational struggles. With revenue on a downtrend over the past five years (-5.73%), coupled with a -17.9 price to cash flow and notable free cash flow deficiencies, the fundamental outlook remains problematic. The company’s cash position is depleting, exacerbated by continuous operational losses.

Technical analysis of AQST’s weekly price patterns reveals a volatile yet modest upward trend influenced by potential catalyst news rather than sustained investor conviction. Following a sharp dip to $4.86, the stock rebounded to $5.6978, illustrating a potential recovery trajectory. Price levels around $4.80 serve as significant support, while $5.70 could act as resistance. Recent price movements suggest an opportunity for short-term trades, primarily capitalizing on FDA-related catalysts, focusing on buying near support and holding toward the identified resistance with vigilant stop-loss measures to mitigate downside risks.

Recent catalysts, particularly the promising FDA update stating no advisory meeting required for Anaphylm’s approval, have significantly boosted investor sentiment, evidenced by share price appreciation. The lack of a required FDA advisory committee meeting for Anaphylm indicates an accelerated approval path, drawing favorable attention from analysts with increased price targets. Compared to industry benchmarks, AQST is positioned for a positive outlook contingent on FDA approval outcomes, yet it remains under scrutiny due to historical financial deficiencies. Investors should watch for price action near $10, supported by analysts’ targets, with overall sentiment cautiously positive pending regulatory outcomes.

Candlestick Chart

Weekly Update Sep 15 – Sep 19, 2025: On Sunday, September 21, 2025 Aquestive Therapeutics Inc. stock [NASDAQ: AQST] is trending up by 15.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Aquestive Therapeutics recently experienced a remarkable surge in stock price, reflecting market optimism projected from strategic developments around its Anaphylm product. Penning in the latest numbers, the closing price indicated a positive swing, reaching $5.6978, after oscillating between $5.67 and $5.72. This uptick indicates investor confidence following the announcement of clear approval pathways with the FDA, which provided clarity and justified the price momentum.

Financial metrics reveal the company operating with a substantial gross margin of 61.1%, underpinning their healthy cost management strategies. Despite operating losses, strategic movements indicate plans to exploit new market areas could capitalize on future positive gains. Recent data also points to improving share liquidity which aids in establishing a more favorable pricing environment, supported by a mean analytical price target of $8.78, signaling sustained investor belief in the stock’s growth prospect.

More Breaking News

In terms of fundamental insights, key ratios display certain challenges, yet liquidity ratios showcase resilience with a current ratio of 3.5. While revenue streams might not fully take off considering past declining trends, the sentiment around Anaphylm’s launch repositions Aquestive as a resurgent force within the commercial pharmaceutical landscape. There’s a noticeable anticipation that new drug developments will structurally benefit the company’s bottom line once market penetration advances.

Conclusion

Aquestive Therapeutics stands on the cusp of defining strides with its recent regulatory milestones and burgeoning financial backing, evidenced by bullish analyst forecasts. Market participants are urged to remain attuned to subsequent developments, focusing on strategic execution quality and navigating regulatory waters effectively. As the FDA aligns in favor, further consolidating their pipelines could translate into broader market share gains, positioning the company to ride a transformative wave in crisis response therapeutics.

In summary, the vacuum of operational adversities coupled with favorable receptions of Anaphylm forecast a buoyant future for Aquestive Therapeutics and presents an invigorating narrative for stakeholders, as market dynamics nudge anticipatory direction towards lucrative valuations and ascendancy within pharmaceutical circles. Traders should remain vigilant for dynamic shifts in valuations post-strategic release initiatives, ready to pivot alongside emerging updates, particularly around Anaphylm’s scheduled strategic rollouts. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” Therefore, it is crucial to not rush into trades but to watch for the optimal conditions that align with these strategic milestones.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”